Krystal Biotech Sells PVA for $100M to Undisclosed Buyer

Krystal Biotech is offloading its priority review voucher (PRV) for a cool $100 million to an undisclosed buyer, a practice that nets companies cash — in highly variable amounts.
Source: Drug Industry Daily